Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references11 references

Structure reference·

3D coordinates·Sequence matchexperimental

Sequence match·reference selected·identity 100.0%·confidence experimental

Link	Method	Confidence	Match
Open	Sequence match	experimental	100.0% identity
Open	Sequence match	experimental	100.0% identity
Open	Sequence match	experimental	100.0% identity
Open	Sequence match	experimental	100.0% identity
Open	Sequence match	experimental	100.0% identity
Open	Sequence match	experimental	100.0% identity
Open	Sequence match	experimental	100.0% identity
Open	Sequence match	experimental	100.0% identity
Open	Sequence match	experimental	100.0% identity
Open	Sequence match	experimental	97.2% identity
Open	Homology model	predicted	36 aa

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors36 aa · pI 4.0 · GRAVY -0.88

Length: 36 aa
Monoisotopic mass: 4448.16 Da
Average mass: 4450.88 Da
Net charge at pH 7.4: -4.90
Estimated pI: 4.02
GRAVY: -0.875
KD-positive residues: 27.8%
Aromatic residues: 13.9%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 0.63
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

3.92

pH 5

-3.25

pH 6

-4.16

pH 7.4

-4.95

pH 9

-5.82

pH 12

-8.87

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)

7 · 19.4%

Basic (K,R,H)

3 · 8.3%

Polar uncharged (N,Q,S,T)

12 · 33.3%

Hydrophobic aliphatic (A,V,I,L,M)

9 · 25.0%

Aromatic (F,W,Y)

5 · 13.9%

Top residues

E616.7%L616.7%Q411.1%S411.1%N38.3%W38.3%I25.6%K25.6%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

3-9

SLIHSLI

GRAVY 1.686

Most hydrophilic window

13-19

QNQQEKN

GRAVY -3.557

30 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

12 aa window

3-14

SLIHSLIEESQN

μH 1.69 · charge -1.9

12 aa window

4-15

LIHSLIEESQNQ

μH 1.46 · charge -1.9

12 aa window

2-13

TSLIHSLIEESQ

μH 1.45 · charge -1.9

15 aa window

4-18

LIHSLIEESQNQQEK

μH 1.30 · charge -1.9

15 aa window

3-17

SLIHSLIEESQNQQE

μH 1.26 · charge -2.9

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Oxidation-sensitive residues

W · pos 29, 33, 35

Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 0.63100°/residue · 36 aa

Hydrophobic moment0.63

Mean K-D hydropathy-0.87

Approx. net charge-5

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.Sequence > 30 aa — only termini and every fifth position are numbered because later turns share earlier wheel angles.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

89.44

Instability index

62.6

Above 40 — predicted unstable in vitro.

Boman index

2.02 kcal/mol

Molar extinction coefficient (280 nm)

17,990 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 4.04

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Exposure / Absorption

6 records

What evidence describes systemic exposure or absorption?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context in preview

Quantitative results that may be analysed only with scientifically compatible records.

Reported results in preview

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBioavailability AUC Cmax Tmax

Loading 6 Exposure / Absorption records…

Distribution / Barrier

6 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context in preview

Quantitative results that may be analysed only with scientifically compatible records.

Reported results in preview

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopePlasma protein binding Vd

Loading 6 Distribution / Barrier records…

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Excretion / Persistence

16 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context in preview

Quantitative results that may be analysed only with scientifically compatible records.

Reported results in preview

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeHalf Life Clearance

Loading 16 Excretion / Persistence records…

Toxicity / Safety

2 records

What safety, toxicity, or tolerability evidence is attached?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scope% cytotoxicity

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

% cytotoxicity2 records · 2 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	50 %	Eligible when experimental context matches	Human embryonic kidney HEK293T cells · Human embryonic kidney HEK293T cells · human	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
2	50 %	Eligible when experimental context matches	Human PBMC · Human PBMC · human	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

Summary1 linked product

Linked products: 1
Label context: None
Clinical trials: 25
Safety label cues: None

Linked products1 shown

Enfuvirtide

Peptide-product match

Unique peptide match

Route / product class

Subcutaneous · HIV Fusion Inhibitors

Clinical context

25 trial records · 12 exact intervention matches · 10 with results · latest 2025-12-26

Label safety context

No label safety cue linked

View product

Identity & reference map

30 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary11 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 11
Measurements: 30
ATL peptide ID: ATLPC0006962

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 30

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 30

Different notation

Reported notation does not resolve to the current display sequence.

2 / 30

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

28 / 30

Reported sequence notation

Different2 references

Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF

Current identity

YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF

Reported names

No distinct human-readable aliases are exposed.

Reference map11 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	Persistence Half Life	No reported alias	5 identity 5 evidence
Reference Open	Persistence Half Life	No reported alias	4 identity 4 evidence
Reference Open	Identity only	No reported alias	7 identity 0 evidence
Reference Open	DistributionExposure Area Under Curve, Volume Of Distribution	No reported alias	3 identity 2 evidence
Reference Open	Persistence Half Life	No reported alias	2 identity 2 evidence
Reference Open	Safety Cytotoxicity Percent Observation	No reported alias	2 identity 2 evidence
Source record Open	DistributionExposure Bioavailability, Plasma Protein Binding	No reported alias Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFdifferent	2 identity 2 evidence
Reference Open	Persistence Half Life	No reported alias	1 identity 1 evidence
Reference Open	Persistence Half Life	No reported alias	1 identity 1 evidence
Reference Open	Persistence Half Life	No reported alias	1 identity 1 evidence

1–10 / 11

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0006962
Identity type: canonical sequence
ADMET endpoints: 9
Evidence records: 30
Reference groups: 11
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0006962

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0006962' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0007610

—

Notation only

Link

Method

Confidence

Match

Open

Sequence match

experimental

100.0% identity

Open

Sequence match

experimental

100.0% identity

Open

Sequence match

experimental

100.0% identity

Open

Sequence match

experimental

100.0% identity

Open

Sequence match

experimental

100.0% identity

Open

Sequence match

experimental

100.0% identity

Open

Sequence match

experimental

100.0% identity

Open

Sequence match

experimental

100.0% identity

Open

Sequence match

experimental

100.0% identity

Open

Sequence match

experimental

97.2% identity

Open

Homology model

predicted

36 aa

Value

Analysis use

Assay / model

Result context

Reference

50 %

Eligible when experimental context matches

Human embryonic kidney HEK293T cells · Human embryonic kidney HEK293T cells · human

Result: Reported point value · Molecular form: not reported · Source: Primary reference linked

Reference

50 %

Eligible when experimental context matches

Human PBMC · Human PBMC · human

Result: Reported point value · Molecular form: not reported · Source: Primary reference linked

Reference

Supports

Reported identity

Records

Reference

Open

Persistence

Half Life

No reported alias

5 identity

5 evidence

Reference

Open

Persistence

Half Life

No reported alias

4 identity

4 evidence

Reference

Open

Identity only

No reported alias

7 identity

0 evidence

Reference

Open

DistributionExposure

Area Under Curve, Volume Of Distribution

No reported alias

3 identity

2 evidence

Reference

Open

Persistence

Half Life

No reported alias

2 identity

2 evidence

Reference

Open

Safety

Cytotoxicity Percent Observation

No reported alias

2 identity

2 evidence

Source record

Open

DistributionExposure

Bioavailability, Plasma Protein Binding

No reported alias

Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFdifferent

2 identity

2 evidence

Reference

Open

Persistence

Half Life

No reported alias

1 identity

1 evidence

Reference

Open

Persistence

Half Life

No reported alias

1 identity

1 evidence

Reference

Open

Persistence

Half Life

No reported alias

1 identity

1 evidence

Enfuvirtide

Sequence & molecular identity

Sequence & peptidoform

Structure & chemistry

Physicochemical profile

Computed developability descriptors

Exposure / Absorption

Distribution / Barrier

Excretion / Persistence

Toxicity / Safety

Evidence landscape

Product context

Enfuvirtide

Identity & reference map

Data access & reproducibility

Structured peptide profile

Peptide catalogue

Measurement catalogue

Enfuvirtide

Sequence & molecular identity

Sequence & peptidoform

Structure & chemistry

Physicochemical profile

Computed developability descriptors

Exposure / Absorption

Distribution / Barrier

Excretion / Persistence

Toxicity / Safety

Evidence landscape

Product context

Enfuvirtide

Identity & reference map

Data access & reproducibility

Structured peptide profile

Peptide catalogue

Measurement catalogue